- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright cuts OKYO Pharma stock price target to $5 on share count | 1 | Investing.com | ||
| Mi | OKYO Pharma Says FDA Supports Advancement Of NEPTUNE Clinical Trial For Urcosimod | 2 | RTTNews | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial | 2 | Investing.com | ||
| Mi | OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain | 304 | GlobeNewswire (Europe) | FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE... ► Artikel lesen | |
| 07.07. | OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium | 265 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 07.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 19.05. | OKYO Pharma appoints Marta Sacchetti to advisory board | 2 | Investing.com | ||
| 19.05. | OKYO Pharma LTD: OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD | 415 | GlobeNewswire (Europe) | Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO's introduction to the broader ophthalmology community at ASCRS... ► Artikel lesen | |
| 19.05. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.04. | OKYO Pharma LTD: OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May | 402 | GlobeNewswire (Europe) | Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO... ► Artikel lesen | |
| 29.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.04. | OKYO Pharma beruft Expertengremium zu Medikamentenkandidat Urcosimod ein | 3 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma plant Expertentreffen zu Urcosimod auf ASCRS-Jahrestagung | 1 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma to hold advisory board meeting at ASCRS conference | 1 | Investing.com | ||
| 07.04. | OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting | 362 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 07.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 393 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Director Acquires Shares | 446 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Chief Development Officer and Director Acquires Shares | 476 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 18.03. | OKYO Pharma reports quality of life improvements in pain trial | 2 | Investing.com |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,890 | +0,77 % | Handelsvolumen bei Novavax-Optionen erreicht Mehrmonatshoch | ||
| PALATIN TECHNOLOGIES | 9,990 | +4,06 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,258 | +1,13 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,318 | -3,64 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| IDEXX LABORATORIES | 494,60 | -0,20 % | IDEXX Laboratories Earnings Preview: What to Expect | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,316 | +0,19 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| REDHILL BIOPHARMA | 0,690 | -0,43 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,381 | -3,30 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 14,250 | +0,92 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 162,45 | +0,56 % | Dem Krebs den Stecker ziehen: Agios Pharmaceuticals, Revolution Medicines und Vidac Pharma | Ohne Gesundheit ist alles nichts. In den vergangenen Jahren haben Unternehmen aus den Bereichen Pharma und Biotech bereits große Erfolge erzielt, wenn es darum geht, die Leiden chronisch Kranker oder... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,600 | -1,15 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOXCEL THERAPEUTICS | 0,814 | +3,04 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,500 | +7,03 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,888 | +1,62 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,890 | 0,00 % | Palisade Bio, Inc.: Palisade Bio to Participate in the Leerink Partners Therapeutics Forum |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,005 (+0,32 %) liegt der Kurs bei 1,555 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.